B6-Pnpla3*I148M Mouse
製品名
B6-Pnpla3*I148M Mouse
製品ID
C001692
系統名
C57BL/6JCya-Pnpla3tm1(I148M)/Cya
背景情報
C57BL/6JCya
状況
このマウス系統を論文で使用する場合は、「B6-Pnpla3*I148M Mouse（カタログ番号C001692）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
遺伝子名
遺伝子別名
Adpn
NCBI ID
染色体
Chr 15
MGI ID
さらに
系統詳細
The PNPLA3 gene encodes a triglyceride lipase that mobilizes polyunsaturated fatty acids and promotes the secretion of large very-low-density lipoproteins by the liver. It is mainly expressed in the liver, adipose tissue, and hepatic stellate cells, participating in lipid metabolism, especially triglyceride hydrolysis and lipid droplet remodeling. Its I148M mutation is significantly associated with metabolism-associated fatty liver disease (MASLD), alcoholic liver disease, and liver fibrosis. The I148M mutant, as an inhibitor of PNPLA2/ATGL-mediated lipolysis, disrupts lipid droplet metabolism and promotes hepatic steatosis [1]. PNPLA3 is highly upregulated in a high-carbohydrate diet, and the I148M variant exacerbates the harmful effects of a high-sucrose diet on non-alcoholic fatty liver. Targeted degradation of PNPLA3 I148M through means such as shRNA-mediated gene knockout or siRNA can reduce protein abundance and alleviate steatosis [2-3].
B6-Pnpla3*I148M mice are obtained by introducing the I148M mutation into the mouse Pnpla3 gene using gene editing technology. Homozygous B6-Pnpla3*I148M mice are viable and fertile. This model can be used for research on the disease mechanisms and treatment methods of metabolism-associated fatty liver disease (MASLD), alcoholic liver disease, and liver fibrosis.
参考文献
Johnson SM, Bao H, McMahon CE, Chen Y, Burr SD, Anderson AM, Madeyski-Bengtson K, Lindén D, Han X, Liu J. PNPLA3 is a triglyceride lipase that mobilizes polyunsaturated fatty acids to facilitate hepatic secretion of large-sized very low-density lipoprotein. Nat Commun. 2024 Jun 6;15(1):4847.
Mashek DG. Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD. Mol Metab. 2021 Aug;50:101115.
Murray JK, Long J, Liu L, Singh S, Pruitt D, Ollmann M, Swearingen E, Hardy M, Homann O, Wu B, Holder JR, Sham K, Herberich B, Lo MC, Dou H, Shkumatov A, Florio M, Rulifson IC. Identification and Optimization of a Minor Allele-Specific siRNA to Prevent PNPLA3 I148M-Driven Nonalcoholic Fatty Liver Disease. Nucleic Acid Ther. 2021 Oct;31(5):324-340.
系統作製戦略
Figure 1. Gene editing strategy of B6-Pnpla3*I148M mice. The p.I148M (ATT to ATG) point mutation was introduced into exon 3 in 5’ homology arm of the targeting vector.
適用分野
Research on the disease mechanisms and treatment methods of metabolism-associated fatty liver disease (MASLD), alcoholic liver disease, liver fibrosis, etc;
Research on PNPLA3 I148M inhibitors.
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。